Torrent Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zgezx39p96o0ue0mzdyx4z04.pdf

Key Takeaways


India Business & the Semaglutide Opportunity

Aman Mehta: "our approach has anyway been to look at market share first and profitability later, and hopefully by next year I think it should start reversing."

JB Pharma Integration & Synergies

Aman Mehta: "What was expected next year may be delivered this year. Next year whether the actual synergy number is higher or not, that we can share maybe in a couple of more quarters."

Brazil: Growth Engine with a Semaglutide Timing Gap

Sanjay Gupta: "Ozempic is going declining very fast and Wegovy is growing very fast... all the companies so far that have filed have filed Ozempic. There have been no filers of Wegovy."

International Markets: Mixed Trajectories


Pipeline & R&D Allocation

Aman Mehta: "Our objective is that any new such launch should add incrementally minimum 1% to 2% to the total India growth over the first year or two years of launch."

Guidance & Commitments

CommitmentSpecificsTimeline
India organic growthMid-teens growth realisticFY27, absent external demand shocks
Semaglutide oral marginsReach reasonably high level as API prices dropNext 6 to 12 months
Semaglutide franchise profitabilityEBITDA margin should start reversingBy next year (FY27)
Brazil top-line growth10% to 15%FY26-27
Germany constant-currency growthLow single-digit, below 5%Next year
US growthSingle-digitNext couple of years, before major product launch
JB Pharma cost synergiesUp to INR 450 crores total, ~20% in year 1, phasing potentially earlierBy year 3; year 1 tracking ahead
JB Pharma revenue synergiesNo material contributionThis year
Resmetirom (NASH) launchWithin 12 to 18 months, after patent expiryPatent expires within next year
India MR countExpand Torrent to 7,500, then freeze post-JB mergerFY27
Oral Semaglutide pricingNo further reduction from ₹109 per tabletOngoing
Germany biosimilar tendersBegin participatingJune-July timeframe

Key Metrics

MetricQ4 FY26
Consolidated revenue₹4,197 cr, up 42% YoY
Operating EBITDA₹1,356 cr, up 41% YoY
Operating EBITDA margin32.3% (combined); 32.7% ex-JB
India business revenue₹2,215 cr, up 43% YoY (includes JB); base business ex-JB up 15% vs IPM growth of 10%
Brazil constant currency revenueBRL 25.9 cr, up 11% YoY; IQVIA growth 17% vs market 6%
US constant currency revenueUSD 3.8 cr, up 9% YoY
Germany constant currency revenueEUR 3.1 cr, down 1% YoY
Full-year overall revenue growth15% (FY26)
Full-year operating EBITDA margin32.7% (FY26)
Net debt to EBITDA2.3x, considering JB's full-year FY26 EBITDA
Final dividend₹9 per equity share
India field force7,100 ex-JB at year-end; plan to reach 7,500 in FY27
Semaglutide generic market share38% overall, 28% injectable, 100% oral (PharmaTrac April data)
Semaglutide April sales~₹17 cr total (both brands, all formats); oral ₹6 cr, injectable ₹11 cr
Curatio business growth27% in FY26
Brazil volume growthFlat to slightly negative in Q4
Brazil price increase5% in Q4
Brazil new introductions contribution~7% in Q4
Brazil molecules awaiting ANVISA approval58
R&D spend~5% of sales in FY26; incremental 0.5% expected in FY27
Cost synergy guidance (JB Pharma)Up to ₹450 cr by year 3; ~20% in year 1
Torrent base business attritionHigh single-digit
India base business PharmaTrac growth breakup3.8% volume, 6.7% price, 3.4% new products (vs market 1.7%, 5.5%, 3.3%)
Semaglutide internal sales projection₹200 cr to ₹250 cr at this stage
Oral Semaglutide price₹109 per tablet, reduced from ₹149
Amortization charge (JB acquisition)₹257 cr; net negative after deferred tax reversal of ~₹62-63 cr is minus ₹195 cr
JB PAT for stub period₹143 cr
Exceptional items₹46 cr (Torrent), ₹19 cr (JB), both in Q4